[go: up one dir, main page]

AU7205894A - Purified natural and synthetic compounds for the treatment of osteoarthritis - Google Patents

Purified natural and synthetic compounds for the treatment of osteoarthritis

Info

Publication number
AU7205894A
AU7205894A AU72058/94A AU7205894A AU7205894A AU 7205894 A AU7205894 A AU 7205894A AU 72058/94 A AU72058/94 A AU 72058/94A AU 7205894 A AU7205894 A AU 7205894A AU 7205894 A AU7205894 A AU 7205894A
Authority
AU
Australia
Prior art keywords
osteoarthritis
treatment
synthetic compounds
purified natural
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72058/94A
Inventor
Peter V Hauschka
Peter T. Lansbury Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEOGENIX Inc
Original Assignee
NEOGENIX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEOGENIX Inc filed Critical NEOGENIX Inc
Publication of AU7205894A publication Critical patent/AU7205894A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU72058/94A 1993-06-08 1994-06-08 Purified natural and synthetic compounds for the treatment of osteoarthritis Abandoned AU7205894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7318993A 1993-06-08 1993-06-08
US073189 1993-06-08
PCT/US1994/006490 WO1994028889A1 (en) 1993-06-08 1994-06-08 Purified natural and synthetic compounds for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
AU7205894A true AU7205894A (en) 1995-01-03

Family

ID=22112274

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72058/94A Abandoned AU7205894A (en) 1993-06-08 1994-06-08 Purified natural and synthetic compounds for the treatment of osteoarthritis

Country Status (2)

Country Link
AU (1) AU7205894A (en)
WO (1) WO1994028889A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795560B1 (en) * 1994-12-01 2003-12-10 Seikagaku Corporation Keratan sulfate oligosaccharide fraction and drug containing the same
CA2232527C (en) * 1995-09-19 2008-09-02 Seikagaku Corporation Anti-inflammatory agent
DE69729004T2 (en) * 1996-10-10 2005-04-07 The General Hospital Corp., Boston PHOTODYNAMIC THERAPY FOR THE TREATMENT OF OSTEOSRTHRITIS
WO1998025631A1 (en) * 1996-12-13 1998-06-18 Lescarden, Inc. Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
CN1287852C (en) * 1997-07-14 2006-12-06 村松乔 Drugs contg. as active ingredient midkine or inhibitors thereof
US20010041743A1 (en) * 2000-01-12 2001-11-15 Steven Offenbacher Use of cyclopentenone derivatives for bone and periodontal regeneration
CA2431709A1 (en) 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
HUP0400659A3 (en) * 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
EP1435980A4 (en) 2001-09-15 2006-06-07 Univ California STRATIFIED CORTOR FABRIC AND METHOD OF HOLDING THE SAME
US6933298B2 (en) 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
US20030138873A1 (en) * 2002-01-22 2003-07-24 Koichi Masuda Tissue engineered cartilage for drug discovery
CA2474269A1 (en) 2002-01-23 2003-07-31 Institute Of Nutraceutical Research Pty Ltd Nutraceuticals for the treatment, protection and restoration of connective tissues
US6716853B2 (en) 2002-03-02 2004-04-06 Aventis Pharma Deutschland Gmbh Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
US7166609B2 (en) 2002-11-02 2007-01-23 Sanofi-Aventis Deutschland Gmbh Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
US7205315B2 (en) 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
FR2864089B1 (en) * 2003-12-19 2006-02-03 Aventis Pharma Sa CHONDROID SULFATE CARBOXY-REDUCED DERIVATIVES, THEIR PREPARATION, THEIR APPLICATION AS MEDICINE AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
FR2864090B1 (en) * 2003-12-19 2006-01-27 Aventis Pharma Sa CARBOXY-REDUCED HYALURONIC ACID DERIVATIVES, THEIR PREPARATION, THEIR USE AS A MEDICINAL PRODUCT AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
FR2864087B1 (en) * 2003-12-19 2006-01-27 Aventis Pharma Sa DERMATAN SULFATE CARBOXY-REDUCED DERIVATIVES, THEIR PREPARATION, THEIR MEDICINAL APPLICATION AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
DE102004004974A1 (en) 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-imino acid derivatives as inhibitors of matrix metalloproteinases
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8114841B2 (en) 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
ES2443581T3 (en) 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Compositions and methods for bone treatment
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
EP2538791B1 (en) 2010-02-22 2015-04-08 BioMimetic Therapeutics, LLC Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
WO2014164723A1 (en) * 2013-03-12 2014-10-09 The Johns Hopkins University Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
FR2585576B1 (en) * 1985-07-30 1992-01-03 Bioetica Sa BONE MATRIX REPLACEMENT PROMOTING OSTEOGENESIS
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
US5036056A (en) * 1987-07-08 1991-07-30 Martin Kludas Methods for treating damaged corneal, uterine, or cartilage tissue
US5171674A (en) * 1988-07-13 1992-12-15 Brigham And Women's Hospital Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US5246013A (en) * 1989-12-22 1993-09-21 Massachusetts Institute Of Technology Probe, system and method for detecting cartilage degeneration
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5206354A (en) * 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2

Also Published As

Publication number Publication date
WO1994028889A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
AU7205894A (en) Purified natural and synthetic compounds for the treatment of osteoarthritis
AU7419096A (en) Treatment of vegetables
AU6797094A (en) Cosmetic treatment of substrates
AU5389194A (en) Wastewater treatment
AU2103295A (en) Methods for the treatment of thrombosis
AU1173195A (en) Treatment of immunoregulatory disorders
AU1115095A (en) Treatment of cellulose
AU618231B3 (en) Treatment of emulsions
AU3007492A (en) Treatment of wastewater
ZA94338B (en) Treatment of waste petroleum
AU1278295A (en) Wastewater treatment
AU6723294A (en) Use of simmondsine
AU1650792A (en) Treatment of polyurethane surfaces
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU3553489A (en) Novel compounds and treatment
AU3380793A (en) Treatment of waste or other material
AU6662794A (en) Composition for the treatment of impaired hair growth
AU2875092A (en) Methods for the treatment of hyperlipidemia using azaspiranes
AU1587295A (en) The treatment of gaseous substances
AU1604692A (en) Treatment of longitudinally extending members
AU5813694A (en) Treatment of plant material
AU8819691A (en) Treatment of gas
AU3034392A (en) Treatment of liquids
ZA948930B (en) Treatment of compost
AU5463694A (en) Process for increasing the protein content of plants